We welcome two special guests, Dr. Stacy Lindborg, and Dr. Premal Thaker, to discuss the results of the OVATION 2 Study and ...

The European Commission has approved BRAFTOVI® and MEKTOVI® for treating advanced non-small cell lung cancer with the BRAFV600E mutation.

The FDA has approved the Altius® System, an innovative device for managing chronic pain in lower limb amputees. Utilizing ...

The FDA has approved Illumina's TruSight Oncology Comprehensive test as a companion diagnostic for two cancer indications.

The application for nipocalimab was submitted to the FDA for the treatment of generalized myasthenia gravis, following ...

In this exclusive interview, we welcome Caroline Loew, CEO of Mural Oncology, to discuss the potential of cytokine-based immunotherapies for cancer treatment. Additionally, we will explore the ...

Dr. Reggie Ewesuedo, Vice President of Clinical Development at Lantern Pharma, discussed 'Breakthroughs in Lung Cancer Treatment for Never Smokers,' including the novel AI-assisted drug candidate, ...

The first human trial of BNT116, an mRNA-based lung cancer vaccine, has started, and the first patient received the treatment at UCLH. Developed by BioNTech, the vaccine targets non-small cell lung ...

The novel cancer drug, PT217, has received FDA Orphan Drug Designation for treating neuroendocrine carcinoma (NEC). PT217, which targets DLL3 and CD47, offers new hope for NEC patients, typically ...